Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



AbbVie and Shire: This Deal Is Happening

U.S stocks are climbing back toward this month's record high on Monday morning, with the benchmark S&P 500 and the narrower Dow Jones Industrial Average (DJINDICES: ^DJI  ) up 0.51% and 0.72%, respectively, at 10:15 a.m. EDT. Pharmaceutical companies are once again "lighting up the board" this morning, with news that AbbVie (NYSE: ABBV  ) has made a fifth offer for Shire (NASDAQ: SHPG  ) ; the two companies are now in advanced negotiations to finalize the $53 billion deal.

A deal is going to get done. This morning, Shire announced that it "requested and has received a further revised proposal from AbbVie" on Sunday. This is AbbVie's fifth offer, and Shire says it is willing to endorse an offer on these financial terms "subject to satisfactory resolution of the other terms of the offer" (which Shire's board is currently negotiating with AbbVie).

Just what are the new financial terms? AbbCie's latest offer comprises $41.83 in cash and 0.896 shares of AbbVie per Shire share. That offer is worth $91.04 based on Friday's closing prices -- a 42% premium to Shire's closing share price on Jun. 19, the last day prior to AbbVie's interest becoming public knowledge. As of 9:45 a.m. EDT, with AbbVie trading at $54.50, the offer is now worth $90.74, a 7% premium to the price of Shire shares on the London Stock Exchange. Manifestly, the market believes the deal will happen on terms that are at least as attractive as those AbbVie is now offering.

What would AbbVie be getting for that price? First, the potential transaction is notable for its "inversion" feature, according to which AbbVie would switch its tax domicile to the U.K. (Shire is currently domiciled in Ireland), thus avoiding the 35% U.S. repatriation tax on overseas cash holdings and benefiting from a lower corporate tax rate. This is a highly prized perk; in fact, it was a driving factor behind Pfizer's failed pursuit of AstraZeneca earlier this year.

Shire's best-selling drug, Vyvanse, treats attention deficit hyperactivity disorder, but under new CEO Flemming Ornskov, the company has started building an attractive rare-diseases franchise. Rare diseases are a fast-growing, highly lucrative health care segment: Even though patient numbers are relatively small, treatments are expensive (and thus profitable). Last month, Mr. Ornskov announced new targets to double annual sales to $10 billion by 2020.

And speaking of Mr. Ornskov, I think he could be a potential hidden asset in this deal. Though he only joined Shire last May, he has a great track record as a shareholder-friendly manager, and he has had a good start at Shire. Sanford Bernstein & Co. analyst Ronny Gal didn't mince words when he gave Bloomberg his assessment of Ornskov's tenure last month:

So far, very impressive. First, he took an axe to the cost structure. ... None of [the acquisitions he has made] were stupid. They're all interesting assets.

If AbbVie's board is smart, they'll find a way to retain him, though that will be difficult: At 58, AbbVie CEO Rick Gonzalez is just two years older than Mr. Ornskov.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3027737, ~/Articles/ArticleHandler.aspx, 8/31/2015 3:15:24 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Alex Dumortier

Alex Dumortier covers daily market activity from a contrarian, value-oriented perspective. He has been writing for the Motley Fool since 2006.

Today's Market

updated 2 days ago Sponsored by:
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 1.21 0.06%
NASD 4,828.33 15.62 0.32%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/28/2015 4:55 PM
^DJI $16643.01 Down -11.76 -0.07%
ABBV $63.98 Down -0.53 -0.82%
AbbVie Inc. CAPS Rating: ****
SHPG $235.96 Up +3.00 +1.29%
Shire plc (ADR) CAPS Rating: ****